دورية أكاديمية
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.
| العنوان: | Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. |
|---|---|
| المؤلفون: | Sonnenblick, Amir, Salmon-Divon, Mali, Salgado, Roberto, Dvash, Efrat, Pondé, Noam, Zahavi, Tamar, Salmon, Asher, Loibl, Sibylle, Denkert, Carsten, Joensuu, Heikki, Ameye, Lieveke, Van den Eynden, Gert, Kellokumpu-Lehtinen, Pirkko-Liisa, Azaria, Amos, Loi, Sherene, Michiels, Stefan, Richard, François, Sotiriou, Christos |
| المصدر: | International journal of cancer |
| سنة النشر: | 2020 |
| المجموعة: | DI-fusion : dépôt institutionnel de l'Université libre de Bruxelles (ULB) |
| مصطلحات موضوعية: | Sciences bio-médicales et agricoles, CAF, HER2, TILs, breast cancer, reactive stroma |
| الوصف: | We investigated the value of reactive stroma as a predictor for trastuzumab resistance in patients with early HER2-positive breast cancer receiving adjuvant therapy. The pathological reactive stroma and the mRNA gene signatures that reflect reactive stroma in 209 HER2-positive breast cancer samples from the FinHer adjuvant trial were evaluated. Levels of stromal gene signatures were determined as a continuous parameter, and pathological reactive stromal findings were defined as stromal predominant breast cancer (SPBC; ≥50% stromal) and correlated with distant disease-free survival. Gene signatures associated with reactive stroma in HER2-positive early breast cancer (N = 209) were significantly associated with trastuzumab resistance in estrogen receptor (ER)-negative tumors (hazard ratio [HR] = 1.27 p interaction = 0.014 [DCN], HR = 1.58, p interaction = 0.027 [PLAU], HR = 1.71, p interaction = 0.019 [HER2STROMA, novel HER2 stromal signature]), but not in ER-positive tumors (HR = 0.73 p interaction = 0.47 [DCN], HR = 0.71, p interaction = 0.73 [PLAU], HR = 0.84; p interaction = 0.36 [HER2STROMA]). Pathological evaluation of HER2-positive/ER-negative tumors suggested an association between SPBC and trastuzumab resistance. Reactive stroma did not correlate with tumor-infiltrating lymphocytes (TILs), and the expected benefit from trastuzumab in patients with high levels of TILs was pronounced only in tumors with low stromal reactivity (SPBC <50%). In conclusion, reactive stroma in HER2-positive/ER-negative early breast cancer tumors may predict resistance to adjuvant trastuzumab therapy. ; SCOPUS: ar.j ; info:eu-repo/semantics/published |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 1 full-text file(s): application/pdf |
| اللغة: | English |
| العلاقة: | uri/info:doi/10.1002/ijc.32859; uri/info:pmid/31904863; uri/info:scp/85078761123; https://dipot.ulb.ac.be/dspace/bitstream/2013/303144/3/Sonnenblick_et_al-2020-International_Journal_of_Cancer.pdfTest; http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/303144Test |
| الإتاحة: | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/303144Test https://dipot.ulb.ac.be/dspace/bitstream/2013/303144/3/Sonnenblick_et_al-2020-International_Journal_of_Cancer.pdfTest |
| رقم الانضمام: | edsbas.6D4BBC50 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |